Analysts predict the weight loss drug market to grow between $100 billion and $130 billion by 2030, as per a report.

In addition, TransCelerate executives and member organizations, such as Amgen, Eli Lilly, GSK, and more, will present 10 impactful sessions at the conference, addressing critical and relevant topics ...

The top 20 biopharmaceutical companies experienced mixed performance in 2024 amid a dynamic landscape influenced by various ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Though deal value is down, volume is stable (with biopharma deals +17% vs. 2023), but average deal size dropped, as companies shifted focus to look for earlier-stage opportunities with lower price ...

We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...

As founder of Coatue Management, Philippe Laffont oversees $26.9 billion invested in more than 80 stocks, and though he buys ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...

Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals that distract from plans that would hit Americans -- like drug prices.